Zimmer Biomet Holdings (ZBH – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick Wood from Morgan Stanley maintained a Hold rating on the stock and has a $115.00 price target.
Patrick Wood has given his Hold rating due to a combination of factors that reflect both optimism and caution. On the positive side, Zimmer Biomet Holdings has made significant strides in addressing key product gaps, with a vitality index showing improvement and a strategic focus on cementless implants, which are expected to command a premium price. The company’s base markets in orthopedics appear healthy, and there is a clear direction for growth through bolt-on mergers and acquisitions.
However, despite these encouraging signs, there are still areas where trust needs to be solidified, as the company has experienced some idiosyncratic challenges in the past. Additionally, while the setup for Zimmer Biomet this year seems more attractive, the market estimates have been adjusted conservatively. This cautious approach suggests that while the company is on a positive trajectory, it is not yet at a point where a more aggressive rating is warranted.
In another report released on March 7, Wells Fargo also maintained a Hold rating on the stock with a $113.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com